While patients with a weakened immune system are still more likely to die after TAVR than other patients, those deaths are largely not related to the procedure or any other cardiovascular issues. This new meta-analysis explored data from a variety of clinical trials.

Pope Leo XIV told interventional cardiologists their work “stands at the crossroads of science, compassion and ethical responsibility.” When they treat patients, he added, they are treating the heart “both physically and metaphorically, bringing relief to those who suffer.” 

The company expects TAVR sales alone to be as high as $4.9 billion in 2026. Other minimally invasive therapies are projected to make a major impact as well.

The allegation came days after an internal FDA memo linked the vaccines to the deaths of multiple children. A group of former FDA commissioners pushed back against the content of that memo.

The all-cash deal is expected to be finalized in April 2026. With this divestment of its ambulatory labs, Tennessee-based Community Health Systems said it will be better able to focus on its core patient care business.